Roche, AstraZeneca follow Merck's lead with large RNAi investments

Roche and AstraZeneca have followed Merck's lead in investing heavily in the relatively new field of RNA interference gene-silencing treatments. Roche signed with Alnylam Pharmaceuticals, a biotech with expertise in RNA interference treatments, in a licensing deal that could reach $1 billion, while AstraZeneca signed a smaller deal with the U.K.'s Silence Therapeutics, worth just over $400 million. Earlier, Merck obtained its access to RNAi by buying Sirna Therapeutics for $1.1 billion.

View Full Article in:

International Herald Tribune · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC